Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways
Cancer Cell International,
Abstract Background Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as…